Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
This treatment has been approved for sale to the public.
Astellas Pharma Global Development, Inc.
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )
First received: May 24, 2012
Last updated: July 1, 2013
Last verified: July 2013
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This treatment has been approved for sale to the public.|
|Estimated Study Completion Date:||No date given|
|Estimated Primary Completion Date:||No date given|